

SHEFFIELD ECMC



Sheffield

Sheffield Teaching Hospitals **NHS Foundation Trust**

Key People and Figures

The

Of

Sheffield.



ECMC Lead

Professor Sarah Danson

Consultant medical oncologist with special interest in lung cancer, melanoma and rare tumours.

Communications Lead Dr Janet Horsman (j.m.horsman@sheffield.ac.uk)



ECMC Co-lead

Professor Ingunn Holen Scientist with special interest in translational research in bone oncology.

Translational Lead

Prof Janet Brown (j.e.brown@sheffield.ac.uk) **Business Lead** Colette Mann (colette.mann@sth.nhs.uk)

Weston Park Hospital

1 of **4** UK specialist cancer hospitals Catchment: 1.8 million New patients/year: 7,000 ~ 20% of patients on clinical trials

Cancer Clinical Trials Centre: ~70 staff

Sheffield ECMC Focus



Bone Oncology

Sheffield is the leading centre for bone oncology, with trials for all solid tumours. Other areas of strength include:

Thyroid cancer

Brain tumours

Neuroendocrine tumours


Lung Cancer and Mesothelioma

Rare tumours

- **Bladder cancer**
- Sarcoma
- Melanoma
- **Gestational Trophoblastic Disease**

Novel Clinical Approaches

Our portfolio includes use of oncolytic viruses, novel radio-isotope strategies, macrophage-based virotherapy and combination studies with novel and existing agents in a number of different tumour types, as well as advanced imaging.



The Weston Park Cancer Centre

Establishing a new Cancer Centre

In a joint initiative between the University of Sheffield and STH, cancer research activities in Sheffield have been brought together in the new Weston Park Cancer Centre. The mission of the centre is to support world leading basic, translational and clinical cancer research, leading to improved survival rates for patients in our region and beyond.

Prof Thomas Helleday is appointed director of the cancer centre with ECMC lead Prof Sarah Danson as deputy director.



Weston Park Cancer Centre excellence in cancer care and research

Expanding our Workforce

Increasing our capacity

We have made a range of new appointments of key staff to increase our early phase trial capacity, including new Chairs in Translational Oncology (novel therapeutics) and Medical Oncology (bladder cancer), 2 Clinical Fellows (early phase studies, prostate cancer), 2 Senior Research Fellows (imaging, health economics) and 3 research nurses. We have obtained funding for additional staff to support our early phase trial activity (pharmacy, trial laboratory, data management).

Establishing an Early Phase Team

In order to streamline processes, maximise our trial activities and identify best practice, we have formed an ECMC Delivery Group, ECMC Nursing Group and ECMC Data Manager Group.

We have obtained additional funding, allowing us to reach the critical mass to establish an "Early Phase Team", consisting of clinicians, research nurses, data managers and associated supporting administrative/infrastructure roles.

Progressing Early Phase Trials



1. The **ANTELOPE** study assessing bone oncology imaging has now closed after recruiting the planned 89 patients. Analyses are ongoing.

2. The **ZOLMENO** study has opened and recruited its first

Contribution to the ECMC Network

Sheffield has active engagement with a range of ECMC network activities, including the successful 'ECMC North' grouping (with Manchester, Newcastle, Belfast, Liverpool, Glasgow, Edinburgh and associated member Leeds) to exchange ideas and share best practice.



Membership of groups: Sheffield has members of the Lung, Bladder&Renal, Head&Neck, Skin and Breast cancer NCRI CSGs.



4 patients. This study will investigate the differential effects of Zoledronic acid in pre- and post-menopausal patients with early breast cancer.

3. The CARBON study of radium-223 and capecitabine has closed after recruiting the planned 33 patients. Analysis to assess the safety and efficacy of this combination will now occur.

4. The Bone Recovery after Treatment Study (BRATS) study investigating effects of chemotherapy on bone in patients with multiple myeloma has opened and recruited **11** patients in its first three months.

5. The protocol for the **NEPTUNE** study is finalised and is ready for submission. This is a Phase Ib/IIa proof of concept study to investigate the safety and preliminary efficacy of avelumab combined with radium-223 in ER+ve, HER2-ve breast cancer patients with bone metastases.





Research and Development

Ymchwil lechyd a Gofal Cymru Health and Care Research Wales





Leadership roles: Prof Danson is NIHR Speciality Lead for Cancer: Early Phase Trials; providing a link between ECMC and NIHR. She is chairing an educational workshop on early phase oncology research which is open to members of the ECMC Network. Prof Hatton chairs the NCRI Lung Cancer CSG.

Contribute to ECMC activities: Prof Holen and Dr Ottewell are members of the JING faculty, Profs Danson and Holen participate in ECMC leads/strategy meetings. Sheffield has tested the new clinical Trials Finder and 2 of our clinical fellows attended JING.

Hosting meetings: Dr Bernard Corfe is a member of the NIHR **Cancer and Nutrition Infrastructure Collaboration, hosting their** annual meeting in Sheffield in July 2019.

Email us	ecmc@sheffield.ac.uk
Visit us	Weston Park Hospital Whitham Road, Sheffield S10 2SJ
Website	https://www.ecmcnetwork.org.uk/sheffield